Search

Your search keyword '"Ayello, Janet"' showing total 570 results

Search Constraints

Start Over You searched for: Author "Ayello, Janet" Remove constraint Author: "Ayello, Janet" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
570 results on '"Ayello, Janet"'

Search Results

2. Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease

3. Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation.

4. Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model

5. Efficiently targeting neuroblastoma (NB) by the combination of anti-ROR1 CAR NK cells and N-803 in-vitro and in-vivo of NB xenografts

6. Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneously.

7. Adenoviral Cellular Therapy with Adenovirus (ADV)-Specific Cytotoxic T-Lymphocytes (CTLs) for Resistant Infections in Children, Adolescent, and Young Adult (CAYA) Patients Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT): A Promising Approach

12. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma.

13. Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)

15. Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-γ Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

16. Anti-IL1RAP Chimeric Antigen Receptor Modified Ex-Vivo Expanded TGF-Beta Imprinted Natural Killer Cells Against Ewing Sarcoma

17. Manufacture, Immunological Characterization and Clinical Response of GMP Grade Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System

18. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes

19. Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease

22. 303 Targeting Ewing sarcoma with anti-IL1RAP chimeric antigen receptor modified natural killer cells

23. Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma

26. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes.

27. 320 - Safety and Efficacy of High Dose Granulocyte Colony Stimulating Factor Mobilization in Familial Haploidentical Adult Donors with Sickle Cell Trait Followed By CD34+ Cell Enrichment and Mononuclear Cell Add-Back Prior to Haploidentical Allogeneic Transplantation in High-Risk Sickle Cell Disease Recipients

28. Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-Mcam Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells

29. Feasibility, Safety and Efficacy of Haploidentical Viral Cytotoxic T-Lymphocytes for Children, Adolescents, and Young Adults (CAYA) with Refractory Viral Infections in Primary Immunodeficiencies (PID) Post Solid Organ Transplant (SOT) or Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT)

30. Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)

31. Safety and Efficacy of High Dose Granulocyte Colony Stimulating Factor Mobilization in Familial Haploidentical Adult Donors with Sickle Cell Trait Followed By CD34+ Cell Enrichment and Mononuclear Cell Add-Back Prior to Haploidentical Allogeneic Transplantation in High-Risk Sickle Cell Disease Recipients

33. Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma

35. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre-B-ALL

36. An Age-Dependent Pharmacokinetic Study of Intravenous and Oral Mycophenolate Mofetil in Combination with Tacrolimus for GVHD Prophylaxis in Pediatric Allogeneic Stem Cell Transplantation Recipients

38. Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs ® Cytokine Capture System

39. Treatment of Refractory Adenovirus (ADV) Infections Using Adv-Specific Cytotoxic T-Lymphocytes (CTLs) in Children, Adolescents and Young Adults (CAYA) Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID)

40. Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

41. Optimization of Gating of IFN-Gamma Positive Viral Specific Cytotoxic T-Cells (vCTLs) Following Viral Peptivators® Stimulation Utilizing the Cytokine Capture System on the Clinimacs® Prodigy: Quality Control of the Viral CTL Consortium (VIRCTL)

42. Safety and Efficacy of GMP Clinical Grade Manufacturing of Virus Specific Cytotoxic T Lymphocytes (vCTLS) Against Cytomegalovirus (CMV), Epstein Barr Virus ( EBV), Adenovirus (ADV) and BKV to Treat Medically Refractory Viral Infections Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Children, Adolescents and Young Adults (CAYA) (IND# 17449)

43. Stable to Improved Long Term Cardiac and Pulmonary Function in Children, Adolescents, and Young Adults with High Risk Sickle Cell Disease Following Myeloimmunoablative Conditioning and Familial Haploidentical Stem Cell Transplantation

45. T cell depletion utilizing CD34+ stem cell selection and CD3+ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients

46. 423 - Manufacture, Immunological Characterization and Clinical Response of GMP Grade Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System

47. 424 - Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-γ Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

49. 394 - Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)

Catalog

Books, media, physical & digital resources